Fairvalue-Calculator Fairvalue-Calculator
EN DE

Assure Tech (Hangzhou) Co (688075) Fair Value & Analysis

Healthcare · CN · Market cap 4.0B CNY

Price¥29.82
Fair Value¥12.70
Upside-57.4%
Quality95/100
Evidence: High Range ¥9.53 – ¥15.88

Analysis

Assure Tech (Hangzhou) Co (688075) currently trades at ¥29.82, while our model-based Fair Value estimate is ¥12.70 — implying the stock looks roughly 57.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China. It is also involved in POCT and plastic product manufacturing; online sales; pharmaceutical sales; and medical testing. In addition, the company offers drug of abuse, infectious disease, fertility, cardiac marker, tumor marker, allergen, and veterinary tests, as well as Biochemistry, chronic disease monitoring systems, and reader and analyzers. Further, it offers infectious disease, fertility, fecal occult blood, and vaginal pH tests. Assure Tech (Hangzhou) Co., Ltd. was founded in 2008 and is based in Hangzhou, China

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.